220 related articles for article (PubMed ID: 34471678)
1. Modulation of Siglec-7 Signaling Via In Situ-Created High-Affinity
Hong S; Yu C; Rodrigues E; Shi Y; Chen H; Wang P; Chapla DG; Gao T; Zhuang R; Moremen KW; Paulson JC; Macauley MS; Wu P
ACS Cent Sci; 2021 Aug; 7(8):1338-1346. PubMed ID: 34471678
[TBL] [Abstract][Full Text] [Related]
2. Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer.
Daly J; Carlsten M; O'Dwyer M
Front Immunol; 2019; 10():1047. PubMed ID: 31143186
[TBL] [Abstract][Full Text] [Related]
3. Siglec-7 May Limit Natural Killer Cell-mediated Antitumor responses in Bladder Cancer Patients.
Benmerzoug S; Chevalier MF; Villier L; Nguyen S; Cesson V; Schneider AK; Dartiguenave F; Rodrigues-Dias SC; Lucca I; Jichlinski P; Roth B; Nardelli-Haefliger D; Derré L
Eur Urol Open Sci; 2021 Dec; 34():79-82. PubMed ID: 34825225
[TBL] [Abstract][Full Text] [Related]
4. Negative regulation of T cell receptor signaling by Siglec-7 (p70/AIRM) and Siglec-9.
Ikehara Y; Ikehara SK; Paulson JC
J Biol Chem; 2004 Oct; 279(41):43117-25. PubMed ID: 15292262
[TBL] [Abstract][Full Text] [Related]
5. Probing the cis interactions of the inhibitory receptor Siglec-7 with alpha2,8-disialylated ligands on natural killer cells and other leukocytes using glycan-specific antibodies and by analysis of alpha2,8-sialyltransferase gene expression.
Avril T; North SJ; Haslam SM; Willison HJ; Crocker PR
J Leukoc Biol; 2006 Oct; 80(4):787-96. PubMed ID: 16857734
[TBL] [Abstract][Full Text] [Related]
6. Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion.
Hudak JE; Canham SM; Bertozzi CR
Nat Chem Biol; 2014 Jan; 10(1):69-75. PubMed ID: 24292068
[TBL] [Abstract][Full Text] [Related]
7. A Developed NK-92MI Cell Line with Siglec-7
Huang CH; Liao YJ; Fan TH; Chiou TJ; Lin YH; Twu YC
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29617289
[TBL] [Abstract][Full Text] [Related]
8. Identification and functional characterization of a Siglec-7 counter-receptor on K562 cells.
Yoshimura A; Asahina Y; Chang LY; Angata T; Tanaka H; Kitajima K; Sato C
J Biol Chem; 2021; 296():100477. PubMed ID: 33640457
[TBL] [Abstract][Full Text] [Related]
9. The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.
Bärenwaldt A; Läubli H
Expert Opin Ther Targets; 2019 Oct; 23(10):839-853. PubMed ID: 31524529
[No Abstract] [Full Text] [Related]
10. Murine Red Blood Cells Lack Ligands for B Cell Siglecs, Allowing Strong Activation by Erythrocyte Surface Antigens.
Spiller F; Nycholat CM; Kikuchi C; Paulson JC; Macauley MS
J Immunol; 2018 Feb; 200(3):949-956. PubMed ID: 29288201
[TBL] [Abstract][Full Text] [Related]
11. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance.
Jandus C; Boligan KF; Chijioke O; Liu H; Dahlhaus M; Démoulins T; Schneider C; Wehrli M; Hunger RE; Baerlocher GM; Simon HU; Romero P; Münz C; von Gunten S
J Clin Invest; 2014 Apr; 124(4):1810-20. PubMed ID: 24569453
[TBL] [Abstract][Full Text] [Related]
12. Suppressing Immune Responses Using Siglec Ligand-Decorated Anti-receptor Antibodies.
Islam M; Arlian BM; Pfrengle F; Duan S; Smith SA; Paulson JC
J Am Chem Soc; 2022 Jun; 144(21):9302-9311. PubMed ID: 35593593
[TBL] [Abstract][Full Text] [Related]
13. Ganglioside DSGb5, preferred ligand for Siglec-7, inhibits NK cell cytotoxicity against renal cell carcinoma cells.
Kawasaki Y; Ito A; Withers DA; Taima T; Kakoi N; Saito S; Arai Y
Glycobiology; 2010 Nov; 20(11):1373-9. PubMed ID: 20663960
[TBL] [Abstract][Full Text] [Related]
14. Interactions between Siglec-8 and endogenous sialylated cis ligands restrain cell death induction in human eosinophils and mast cells.
Cao Y; Rische CH; Bochner BS; O'Sullivan JA
Front Immunol; 2023; 14():1283370. PubMed ID: 37928558
[TBL] [Abstract][Full Text] [Related]
15. Siglec-7 expression is reduced on a natural killer (NK) cell subset of obese humans.
Rosenstock P; Horstkorte R; Gnanapragassam VS; Harth J; Kielstein H
Immunol Res; 2017 Oct; 65(5):1017-1024. PubMed ID: 28786023
[TBL] [Abstract][Full Text] [Related]
16. Siglec cis-ligands and their roles in the immune system.
Tsubata T
Glycobiology; 2023 Aug; 33(7):532-544. PubMed ID: 37154567
[TBL] [Abstract][Full Text] [Related]
17. Increased Siglec-9/Siglec-9L interactions on NK cells predict poor HCC prognosis and present a targetable checkpoint for immunotherapy.
Xiao R; Tian Y; Zhang J; Li N; Qi M; Liu L; Wang J; Li Z; Zhang J; Zhao F; Wang T; Tan S; Li C; Wu Z; Yu M; Jiang X; Zhan P; Gao L; Han B; Liu X; Liang X; Ma C
J Hepatol; 2024 May; 80(5):792-804. PubMed ID: 38331327
[TBL] [Abstract][Full Text] [Related]
18. Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy.
Yu Y; Peng W
Cancer Biol Med; 2023 May; 20(5):369-84. PubMed ID: 37133224
[TBL] [Abstract][Full Text] [Related]
19. Siglec-5 is an inhibitory immune checkpoint molecule for human T cells.
Vuchkovska A; Glanville DG; Scurti GM; Nishimura MI; White P; Ulijasz AT; Iwashima M
Immunology; 2022 Jun; 166(2):238-248. PubMed ID: 35290663
[TBL] [Abstract][Full Text] [Related]
20. Deacetylated sialic acids modulates immune mediated cytotoxicity via the sialic acid-Siglec pathway.
Grabenstein S; Barnard KN; Anim M; Armoo A; Weichert WS; Bertozzi CR; Parrish CR; Willand-Charnley R
Glycobiology; 2021 Nov; 31(10):1279-1294. PubMed ID: 34192335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
